In the latest installment of Discern Health’s Quality Outlook blog series in the Journal of Clinical Pathways, Partner Tom Valuck and Directors David Blaisdell and Manasi Tirodkar explore how indirect benefits related to the use of cancer care products and services fit into health care value assessments. These indirect benefits include avoidance of costs to patients, caregivers, employers, and society more broadly. In addition, the Discern authors recommend action steps to evaluate and measure the indirect benefits of cancer care to improve coverage and payment in the value-based environment.
“Beyond Face Value: Why Indirect Benefits of Cancer Care Matter” is Discern’s fifth blog post in the Quality Outlook series. The series explores key issues in oncology quality and value through articles focused on measurement, value-based payment, and quality improvement.